Crystalloid
ApprovedSmall molecule
Crystalloid is one of 118 small molecule programs targeting Kidney Injury. It is currently in Approved.
4
Indications
14
Total Trials
0
Active Trials
117
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
178 competitors in Acute Kidney Injury
#DrugCompanyPhaseTrials
1Crystalloid
KKonkuk University Medical Center
Approved
Arginine Vasopressin
SStanford University
Phase 3
Nicotinamide Treatment
AAssistance Publique - Hôpitaux de Paris
Phase 3
IRBESARTAN,
AAssistance Publique - Hôpitaux de Paris
Phase 3
Crestor
AstraZenecaPreclinical
Pentoxyphylline
NNational Taiwan University Hospital
Phase 3
Lexapro
AbbViePreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Celexa
AbbViePreclinical
Lescol
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fluid Resuscitation4 trials
Hypotension2 trials
Postoperative Morbidity1 trial
5 more indications
Kidney Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Crystalloid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- KKonkuk University Medical Center